Effects of Raf Dimerization and Its Inhibition on Normal and Disease-Associated Raf Signaling

Molecular Cell

Volumn 49, Issue 4, 2013, Pages 751-758

  Freeman, Alyson K ^a   Ritt, Daniel A ^a   Morrison, Deborah K ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RAF PROTEIN;

ARTICLE; CARDIOFACIOCUTANEOUS SYNDROME; CONTROLLED STUDY; DIMERIZATION; FACE DISORDER; HEART DISEASE; HUMAN; HUMAN CELL; LEOPARD SYNDROME; NOONAN SYNDROME; PROTEIN FUNCTION; SKIN DISEASE;

AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; HUMANS; MAP KINASE SIGNALING SYSTEM; MICE; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE; NEOPLASMS; PEPTIDE FRAGMENTS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; RAF KINASES; RAS PROTEINS;

EID: 84874225181     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2012.12.018     Document Type: Article

References (24)

1. Allanson J.E., Annerén G., Aoki Y., Armour C.M., Bondeson M.L., Cave H., Gripp K.W., Kerr B., Nystrom A.M., Sol-Church K., et al. Cardio-facio-cutaneous syndrome: does genotype predict phenotype?. Am. J. Med. Genet. C. Semin. Med. Genet. 2011, 157:129-135.
2. Dougherty M.K., Müller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., Conrads T.P., Veenstra T.D., Lu K.P., Morrison D.K. Regulation of Raf-1 by direct feedback phosphorylation. Mol. Cell 2005, 17:215-224.
3. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
4. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 2010, 363:809-819.
5. Gaestel M., Kracht M. Peptides as signaling inhibitors for mammalian MAP kinase cascades. Curr. Pharm. Des. 2009, 15:2471-2480.
6. Garnett M.J., Rana S., Paterson H., Barford D., Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 2005, 20:963-969.
7. Hatzivassiliou G., Song K., Yen I., Brandhuber B.J., Anderson D.J., Alvarado R., Ludlam M.J., Stokoe D., Gloor S.L., Vigers G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
8. Heidorn S.J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J.S., Springer C.J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
9. Marais R., Light Y., Paterson H.F., Mason C.S., Marshall C.J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 1997, 272:4378-4383.
10. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
11. Pandit B., Sarkozy A., Pennacchio L.A., Carta C., Oishi K., Martinelli S., Pogna E.A., Schackwitz W., Ustaszewska A., Landstrom A., et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat. Genet. 2007, 39:1007-1012.
12. Poulikakos P.I., Persaud Y., Janakiraman M., Kong X., Ng C., Moriceau G., Shi H., Atefi M., Titz B., Gabay M.T., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
13. Pritchard C.A., Samuels M.L., Bosch E., McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol. Cell. Biol. 1995, 15:6430-6442.
14. Rajakulendran T., Sahmi M., Lefrançois M., Sicheri F., Therrien M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 2009, 461:542-545.
15. Ritt D.A., Monson D.M., Specht S.I., Morrison D.K. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol. Cell. Biol. 2010, 30:806-819.
16. Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A., Cruz M.S., McCormick F., Rauen K.A. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006, 311:1287-1290.
17. Röring M., Brummer T. Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside. Crit. Rev. Oncog. 2012, 17:97-121.
18. Röring M., Herr R., Fiala G.J., Heilmann K., Braun S., Eisenhardt A.E., Halbach S., Capper D., von Deimling A., Schamel W.W., et al. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO J. 2012, 31:2629-2647.
19. Rushworth L.K., Hindley A.D., O'Neill E., Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell. Biol. 2006, 26:2262-2272.
20. Su F., Bradley W.D., Wang Q., Yang H., Xu L., Higgins B., Kolinsky K., Packman K., Kim M.J., Trunzer K., et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 2012, 72:969-978.
21. Tartaglia M., Gelb B.D., Zenker M. Noonan syndrome and clinically related disorders. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:161-179.
22. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. Cancer Genome Project.
23. Weber C.K., Slupsky J.R., Kalmes H.A., Rapp U.R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 2001, 61:3595-3598.
24. Wellbrock C., Karasarides M., Marais R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 2004, 5:875-885.